Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility = Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility

다국어 초록 (Multilingual Abstract)

Background: Chronic kidney disease (CKD) is a growing public health concern, and available treatments are insufficient in limiting disease progression. New strategies, including regenerative cell-based therapies, have emerged as therapeutic alternatives.
Results from several groups, including our own, have reported evidence of a supportive role for mesenchymal stromal cells (MSCs) in functional recovery and prevention of tissue damage in murine models of CKD. Prompted by these data, an open pilot study was conducted to assess the safety and efficacy of a single injection of autologous adipose tissue-derived MSCs (AT-MSCs) for treatment of CKD.
Methods: AT-MSCs were infused intravenously into six CKD patients at a dose of 1 million cells/kg. Patients were stabilized and followed for one year prior to MSC infusion and one year following infusion. Results: No patients presented with adverse effects. Statistically significant improvement in urinary protein excretion was observed in AT-MSCs transplanted patients, from a median of 0.75 g/day (range, 0.15-9.57) at baseline to 0.54 g/day (range, 0.01-2.66) at month 12 (P = 0.046). The glomerular filtration rate was not significantly decreased post-infusion of AT-MSCs.
Conclusion: Findings from this pilot study demonstrate that intravenous infusion of autologous expanded AT-MSCs into CKD patients was not associated with adverse effects and could benefit patients already undergoing standard medical treatment.

참고문헌 (Reference)

1 de Groot K, "Uremia causes endothelial progenitor cell deficiency" 66 : 641-646, 2004

2 Dou L, "The uremic solutes pcresol and indoxyl sulfate inhibit endothelial proliferation and wound repair" 65 : 442-451, 2004

3 Choi S, "The role of mesenchymal stem cells in the functional improvement of chronic renal failure" 18 : 521-529, 2009

4 Ezquer FE, "Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice" 14 : 631-640, 2008

5 Zerbini G, "Stem cells and the kidney: a new therapeutic tool?" 17 (17): S123-S126, 2006

6 Makhlough A, "Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients" 8 : 116-, 2017

7 Bartolucci J, "Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure : a phase 1/2randomized controlled trial(RIMECARD Trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy])" 121 : 1192-1204, 2017

8 Dorronsoro A, "Regenerating the injured kidney with human umbilical cord mesenchymal stem cellderived exosomes" 4 : 39-, 2013

9 김준섭, "Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy" 대한신장학회 36 (36): 200-204, 2017

10 Ahmad T, "Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy" 33 : 994-1010, 2014

11 Devine SM, "Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates" 101 : 2999-3001, 2003

12 Semedo P, "Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model" 27 : 3063-3073, 2009

13 Moghadasali R, "Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity" 65 : 595-600, 2013

14 Franquesa M, "Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model" 21 : 3125-3135, 2012

15 Villanueva S, "Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model" 121 : 489-499, 2011

16 Alexandre CS, "Lineagenegative bone marrow cells protect against chronic renal failure" 27 : 682-692, 2009

17 Li W, "Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1" 368 : 137-145, 2012

18 Nauta AJ, "Immunomodulatory properties of mesenchymal stromal cells" 110 : 3499-3506, 2007

19 Villanueva S, "Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure" 125 : 199-210, 2013

20 Zhu JH, "Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells" 40 : 648-652, 2006

21 van Koppen A, "Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease" 21 : 2299-2312, 2012

22 Shishehbor MH, "Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease" 101 : 1741-1746, 2008

23 Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy" 345 : 861-869, 2001

24 Semedo P, "Early modulation of inflammation by mesenchymal stem cell after acute kidney injury" 9 : 677-682, 2009

25 Toyserkani NM, "Concise review : a safety assessment of adipose-derived cell therapy in clinical trials : a systematic review of reported adverse events" 6 : 1786-1794, 2017

26 De Ugarte DA, "Comparison of multi-lineage cells from human adipose tissue and bone marrow" 174 : 101-109, 2003

27 Coresh J, "Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000" 16 : 180-188, 2005

28 Papazova DA, "Cell-based therapies for experimental chronic kidney disease : a systematic review and metaanalysis" 8 : 281-293, 2015

29 Verma S, "C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function : further evidence of a mechanistic link between C-reactive protein and cardiovascular disease" 109 : 2058-2067, 2004

30 Makhlough A, "Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease : a safety study with 18 months of follow-up" 20 : 660-669, 2018

31 da Silva AF, "Bone marrow-derived mesenchymal stem cells and their conditioned medium attenuate fibrosis in an irreversible model of unilateral ureteral obstruction" 24 : 2657-2666, 2015

32 Naito T, "Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis" 298 : F683-F691, 2010

33 Shi D, "Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus" 31 : 841-846, 2012

34 Packham DK, "Allogeneic mesenchymal precursor cells(MPC)in diabetic nephropathy : a randomized, placebo-controlled, dose escalation study" 12 : 263-269, 2016

35 Navaneethan SD, "Aldosterone antagonists for preventing the progression of chronic kidney disease" (3) : CD007004-, 2009

36 Tögel F, "Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms" 289 : F31-F42, 2005

37 Hare JM, "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells(prochymal)after acute myocardial infarction" 54 : 2277-2286, 2009

38 Traktuev DO, "A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks" 102 : 77-85, 2008

39 Donadio JV Jr, "A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group" 331 : 1194-1199, 1994